The first product that GLC develops is a noninvasive fecal DNA test for colorectal cancer
screening.  Current medical guidelines recommend regular CRC screening for all adults over
50, an at-risk population of 90 million in the US and 150 million in the EU27. Colorectal
cancer screening is a multi-billion dollar market. At present, no commercial fecal DNA-
based testing products are available.
HOMEABOUT USPRODUCTSNEWSCONTACT US
GLC BIOTECHNOLOGY, INC.
About Colorectal Cancer
A molecular cancer dignostics company
Fecal DNA Test


Fecal DNA Testing for Colorectal Cancer Screening